Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

Research and Innovation Action · Running

GlycanTrigger Glycans as Master Triggers of Health to Intestinal Inflammation Transition

Coordinator
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do Porto, Portugal
Runs
1 January 2023 to 31 December 2028
Status
Running
EU funding
€6.8m
Total cost
€6.8m
Partners
10 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101093997

What the project is doing

In the project's own words, from its summary on CORDIS.

Chronic inflammation underlies several diseases. In Crohn´s disease (CD), there is mounting evidence of a preclinical phase characterized by immunological changes that precede symptoms. Here, we propose a thorough and innovative approach to better understand the health-to-chronic inflammation transition occurring in patients with CD that will be translated in improved disease prediction and prevention. We will address how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms (imposing maladapted host-microbiome interactions) but also systemic mechanisms (promoting anti-microbial antibodies production), involving the novel concept of glycan mimicry as an early trigger of the health to inflammation transition – GlycanTrigger.

Capitalizing on our recent findings showing that changes in the expression of complex branched N-glycans at gut mucosa regulate Inflammatory Bowel Disease immunopathogenesis, we here hypothesize that changes in gut glycocalyx impose early perturbations in host-microbiome interactions, leading to the exposure of altered (glyco)neoantigens, both by pathogens and host epithelial cells which trigger the activation of innate immune response.

Moreover, following our recent discovery that changes in glycosylation can be detected in serum years before CD diagnosis and are correlated with increased levels of pathogenic antimicrobial antibodies (ASCA), we will here pursue the hypothesis that changes in mucosa glycans constitute a major source for the development of anti-glycan antibodies (ASCA), associated with health-to-inflammation transition. The long-term GOAL of this proposal is to unlock, through an integrative approach, a new checkpoint that regulates the transition to chronic inflammation.

Our proposal will lead to breakthrough concepts in the health to chronic inflammation transition and to novel predictive tools translated in novel glyco-intervention strategies for disease prevention.

Who is involved

OrganisationCityCountryRole
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do PortoPortoPortugalCoordinator
International Federation of Crohn's and Ulcerative Colitis AssociationsBruxelles / BrusselBelgiumParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Sorbonne UniversiteParisFranceParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Glsmed Learning Health SALisboaPortugalParticipant
Hospital Da Luz SALisboaPortugalThird party
Sociedade Portuguesa De Inovacao Consultadoria Empresarial E Fomento Da Inovacao SAPortoPortugalParticipant
Ludger LimitedAbingdonUnited KingdomAssociatedpartner
Icahn School of Medicine at Mount SinaiNew YorkUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI